These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 31950149)

  • 1. Glucagon Peptide Family and Adipose Tissue: Not that Intimate, just Acquaintances.
    Perez-Tilve D
    Endocrinology; 2020 Feb; 161(2):. PubMed ID: 31950149
    [No Abstract]   [Full Text] [Related]  

  • 2. Proglucagon-Derived Peptides, Glucose-Dependent Insulinotropic Polypeptide, and Dipeptidyl Peptidase-4-Mechanisms of Action in Adipose Tissue.
    Beaudry JL; Drucker DJ
    Endocrinology; 2020 Jan; 161(1):. PubMed ID: 31782955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum.
    Mentlein R; Gallwitz B; Schmidt WE
    Eur J Biochem; 1993 Jun; 214(3):829-35. PubMed ID: 8100523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dipeptidyl peptidases 8 and 9: specificity and molecular characterization compared with dipeptidyl peptidase IV.
    Bjelke JR; Christensen J; Nielsen PF; Branner S; Kanstrup AB; Wagtmann N; Rasmussen HB
    Biochem J; 2006 Jun; 396(2):391-9. PubMed ID: 16475979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic actions and therapeutic potential of the proglucagon-derived peptides.
    Drucker DJ
    Nat Clin Pract Endocrinol Metab; 2005 Nov; 1(1):22-31. PubMed ID: 16929363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurogenin 3-specific dipeptidyl peptidase-2 deficiency causes impaired glucose tolerance, insulin resistance, and visceral obesity.
    Danilova OV; Tai AK; Mele DA; Beinborn M; Leiter AB; Greenberg AS; Perfield JW; Defuria J; Singru PS; Lechan RM; Huber BT
    Endocrinology; 2009 Dec; 150(12):5240-8. PubMed ID: 19819973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A newly developed glucagon sandwich ELISA is useful for more accurate glucagon evaluation than the currently used sandwich ELISA in subjects with elevated plasma proglucagon-derived peptide levels.
    Kobayashi M; Maruyama N; Yamamoto Y; Togawa T; Ida T; Yoshida M; Miyazato M; Kitada M; Hayashi Y; Kashiwagi A; Kitamura T
    J Diabetes Investig; 2023 May; 14(5):648-658. PubMed ID: 36729958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, and Sodium-Glucose Cotransporter-2 Inhibitors and COVID-19 Outcomes.
    Foresta A; Ojeda-Fernandez L; Macaluso G; Roncaglioni MC; Tettamanti M; Fortino I; Leoni O; Genovese S; Baviera M
    Clin Ther; 2023 Apr; 45(4):e115-e126. PubMed ID: 36933975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comment on "Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study" and a case report of glucagon-like peptide-1 receptor agonist-induced bullous pemphigoid.
    Schwager Z; Mikailov A; Lipworth AD
    J Am Acad Dermatol; 2019 Jun; 80(6):e189-e190. PubMed ID: 30738123
    [No Abstract]   [Full Text] [Related]  

  • 10. Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39).
    Green BD; Mooney MH; Gault VA; Irwin N; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
    Metabolism; 2004 Feb; 53(2):252-9. PubMed ID: 14767880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low soluble dipeptidyl Peptidase-4 levels during acute myocardial infarction and decreased endogenous glucagon like Peptide-1 response are associated with adverse long-term cardiovascular outcome and mortality: A pilot study.
    Mengesha B; Blatt A; Bloch O; Rapoport MJ
    Eur J Clin Invest; 2023 Mar; 53(3):e13897. PubMed ID: 36345656
    [No Abstract]   [Full Text] [Related]  

  • 12. Reply to: "Comment on 'Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study' and a case report of glucagon-like peptide-1 receptor agonist-induced bullous pemphigoid".
    Varpuluoma O; Tasanen K; Huilaja L
    J Am Acad Dermatol; 2019 Jun; 80(6):e191-e192. PubMed ID: 30738121
    [No Abstract]   [Full Text] [Related]  

  • 13. Primary Occurrence of Cardiovascular Events After Adding Sodium-Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Study in Veterans With Diabetes.
    Richardson TL; Halvorson AE; Hackstadt AJ; Hung AM; Greevy R; Grijalva CG; Elasy TA; Roumie CL
    Ann Intern Med; 2023 Jun; 176(6):751-760. PubMed ID: 37155984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the glucagon-like peptide-1 analogue liraglutide versus placebo treatment on circulating proglucagon-derived peptides that mediate improvements in body weight, insulin secretion and action: A randomized controlled trial.
    Kim SH; Abbasi F; Nachmanoff C; Stefanakis K; Kumar A; Kalra B; Savjani G; Mantzoros CS
    Diabetes Obes Metab; 2021 Feb; 23(2):489-498. PubMed ID: 33140542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptidomics of the prolyl peptidases.
    Lone AM; Nolte WM; Tinoco AD; Saghatelian A
    AAPS J; 2010 Dec; 12(4):483-91. PubMed ID: 20552307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study.
    Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Chen WM; Yeh YH; Kuo CT; See LC; Lip GYH
    Cardiovasc Diabetol; 2022 Jun; 21(1):118. PubMed ID: 35765074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current advances and therapeutic potential of agents targeting dipeptidyl peptidases-IV, -II, 8/9 and fibroblast activation protein.
    Chen SJ; Jiaang WT
    Curr Top Med Chem; 2011; 11(12):1447-63. PubMed ID: 21510839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic exposure to high glucose concentrations increases proglucagon messenger ribonucleic acid levels and glucagon release from InR1G9 cells.
    Dumonteil E; Ritz-Laser B; Magnan C; Grigorescu I; Ktorza A; Philippe J
    Endocrinology; 1999 Oct; 140(10):4644-50. PubMed ID: 10499521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-terminally modified glucagon-like peptide-1(7-36) amide exhibits resistance to enzymatic degradation while maintaining its antihyperglycaemic activity in vivo.
    O'Harte FP; Mooney MH; Lawlor A; Flatt PR
    Biochim Biophys Acta; 2000 Mar; 1474(1):13-22. PubMed ID: 10699485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postprandial Dynamics of Proglucagon Cleavage Products and Their Relation to Metabolic Health.
    Wagner R; Eckstein SS; Fritsche L; Prystupa K; Hörber S; Häring HU; Birkenfeld AL; Peter A; Fritsche A; Heni M
    Front Endocrinol (Lausanne); 2022; 13():892677. PubMed ID: 35872982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.